‘Incredible potential’ of cannabis products in healthcare - CPHI Frankfurt preview
![](/46/pdcnewsitem/11/84/20/cannabis%20plant.jpg)
CPHI caught up with Monica Vialpando to discuss developments in the cannabis space and preview her CPHI Frankfurt panel discussion
The market for cannabis products has been growing steadily in recent years, spurred in no small part by the COVID-19 pandemic. As countries locked down, an increasing number of consumers turned to cannabis products to relieve stress, anxiety and improve sleep – causing global legal cannabis sales to jump by 45% in 2020 compared to the previous year.
Now the global market for cannabinoids is valued at more than USD 22.1 billion, with growth of 22% expected between 2022 and 2031.
Increasing acceptance of cannabis products for medical applications is at the heart of this growing industry and, according to Via Innovations CEO Monica Vialpando, we’ve ‘barely scratched the surface’ of their potential benefits. Vialpando will join Amber Wise (Medicine Creek Analytics), Markus Roggen (Delic Labs), and George McBride (Clerkenwell Health) for the panel discussion Lessons from the Future: Cannabis and Psychedelic Industries at CPHI Frankfurt this year – Register for the event here.
Monica Vialpando, CEO, Via Innovations
Lessons from across the Atlantic
Monica Vialpando is the founder and CEO of Via Innovations, a provider of industry-leading formulation, product innovation and development services for global cannabis companies. The company’s cannabis powder – nViable – is the most potent on the market. Leveraging her background as a pharmaceutical development scientist, Vialpando hopes to share her industry learnings with CPHI Frankfurt attendees this year, as well as raising awareness of developments in the cannabis space.
‘There is still skepticism around cannabis research and development that I'm I hoping to clarify with the pharmaceutical audience at CPHI Frankfurt. Coming from the pharmaceutical industry myself, there were a lot of lessons I had to learn about the differences when working with cannabinoids versus pharmaceutical compounds,’ she tells CPHI.
‘I’d like the audience to gain a general understanding and appreciation for the science as well as the lessons learned - especially the regulatory challenges around creating quality products to demonstrate safety and efficacy.’
The panel discussion - which is free for all CPHI Frankfurt attendees - will draw on the speakers’ experience in the North American cannabis and psychedelics markets, with a focus on European development and region-specific challenges.
Vialpando explains: ‘Given our European roots but also having operated primarily in North America, our objective is to bridge the two - not only from a scientific and regulatory standpoint, but also a cultural perspective.’
Researchers from across the pharmaceutical value chain are encouraged to attend, given the depth of untapped potential in the cannabis space.
‘There is incredible potential for the different applications and the medical effects that this plant can produce beyond the more well-known treatments such as pain, sleep, and PTSD. There's a lot more to explore. So, I'm keen on attracting those researchers that are open and willing to help research advancements and understand the best tools to proceed,’ she says.
‘For anyone keen on entering this research space, I want to be able to help with that journey and share some of the good and bad experiences from being in this industry.’
CPHI – At the heart of Pharma
CPHI Frankfurt is the largest international pharma industry event, offering a jam-packed agenda of content and networking opportunities from November 1-3. This year’s event will be a hybrid model, fusing the best elements of traditional, in-person shows with interactive online features to help attendees get the most out of their CPHI experience. For Vialpando, this year’s event serves as a homecoming of sorts.
‘Since entering the cannabis space, I've been focusing on educating the cannabis market on the development of safer products and ways to formulate with cannabinoids. This was a unique opportunity for me to kind of come back home and share what I've learned with my former audience,’ she says.
‘I’m also really looking forward to seeing the latest developments in the formulation development technology landscape. I've been mostly looking into the cannabis industry in the last few years, and now I've started bridging out of it and helping external companies enter through various means, whether it's product development or advisory. But the science keeps going and there's amazing R&D that I haven't stayed up to speed with. So, in the same way I'm trying to bridge the pharmaceutical industry into cannabis, I'm looking forward to using this event to help me bridge back into the pharmaceutical landscape and get up to speed with the latest advancements since I left seven years ago.’
Start your CPHI Frankfurt journey with our Connect to Frankfurt sessions, available on-demand here.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Pharmapack 2024 - From the Floor
Paris once again welcomes Europe’s leading trade show in pharmaceutical packaging and drug delivery innovation. Join our content team as Pharmapack 2024 opens its doors to leading experts and innovators in pharmaceutical packaging and drug delive... -
News On Track at Pharmapack 2024 - The Track Sponsor interview: BD Pharmaceuticals
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Bringing the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 brings exciting opportunities to learn and colla... -
News CPHI Pharma Awards 2023 – API Development and Innovation Winners: Snapdragon Chemistry, a Cambrex Company
After another year of impressive nominations for the CPHI Pharma Awards our winners were announced at CPHI Barcelona in October. In this series of interviews, we speak to the teams behind the award-winning projects, concepts, and technologies. -
News PharmaKure gains authorisation for next stage testing on Alzheimer's treatment
Clinical stage pharmaceutical company PharmaKure gains permission from UK authorities to enter into further testing for PK051 for the treatment of patients with mild cognitive impairment associated with Alzheimer's disease. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News Navigating the Future: Challenges and Opportunities in Pharma Innovation and Investment – CPHI Barcelona 2023 Roundtable Report
In this comprehensive downloadable report, hear from a range of experts in finance and investment in the pharma industry on what investment trends will be shaping the future of the industry, in Catalonia, and the wider world. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance